What do sources say about a first steroid cycle?

What labels and trials give for amounts
TrialDose and schedulePeopleLength
Bhasin 1996, NEJM5Enanthate, 600 mg a week, or placebo, with or without exercise43 normal men10 weeks
Bhasin 2001, Am J Physiol6Enanthate, 25, 50, 125, 300 or 600 mg a week, with a monthly GnRH agonist to suppress their own testosterone61 eugonadal men aged 18-3520 weeks
Pope 2000, Arch Gen Psychiatry7Cypionate, rising to 600 mg a week, and placebo, in crossover56 men aged 20 to 506 weeks on each, 6 weeks apart

None of the labels searched gives a first-cycle length or dose: a survey paper describes cycles of 6 to 12 weeks, and the cypionate and enanthate labels give 50 to 400 mg every 2 to 4 weeks for replacement.123

How long is a cycle, and who says so

A survey paper by Grant and colleagues describes cycling as 6 to 12 weeks on-cycle followed by an off-cycle period when post-cycle therapy is taken.1 None of the DailyMed labels searched for cypionate, enanthate and Xyosted gives a first-cycle length or dose.

What labels and trials give for amounts

The Hikma enanthate label gives 50 to 400 mg every 2 to 4 weeks for male hypogonadism, and the Depo-Testosterone cypionate label gives the same range.23 The Xyosted autoinjector label gives a starting dose of 75 mg under the skin of the abdomen once a week.4

The table is set at the top of the page

In the Bhasin 2001 trial, with the men's own testosterone suppressed, fat-free mass rose dose dependently by 3.4, 5.2 and 7.9 kg at 125, 300 and 600 mg a week.6 An Endocrine Society scientific statement says randomised trials cannot ethically duplicate the large doses and many factors of real use, so outcome data have to come from observational studies.8

How long testosterone lasts

The Depo-Testosterone label gives the half-life of cypionate after intramuscular injection as about eight days.3 The enanthate label gives an interval of every 2 to 4 weeks but no half-life for the enanthate ester; the half-life it reports is for testosterone itself, ranging from 10 to 100 minutes in the literature.2

Strengths, vials and how each ester is given

The Depo-Testosterone label lists two strengths, 100 mg/mL and 200 mg/mL.3 The Hikma enanthate label lists one product, 200 mg/mL in a 5 mL multiple-dose vial.2 Of people who logged testosterone enanthate, 51% set up a 250 mg/mL vial and 25% a 300 mg/mL vial.14

A syringe maker's FDA filing says its insulin syringes are intended for U-100 insulins, and the Humulin R label says that insulin contains 100 units in each milliliter.910

Abuse, dependence and serious reactions

The Depo-Testosterone label says testosterone has been abused, typically at doses higher than recommended for the approved indication and with other anabolic steroids, that this can lead to serious cardiovascular and psychiatric adverse reactions, and that the drug has not been shown to be safe and effective for enhancing athletic performance.3 It also says above-therapeutic doses may bring withdrawal symptoms lasting weeks or months.3 In the Pope 2000 placebo-controlled crossover trial of 56 men aged 20 to 50, 42 of 50 on 600 mg a week had minimal psychiatric effects, 6 became mildly hypomanic and 2 markedly hypomanic.7

Natural testosterone, fertility and recovery

The Depo-Testosterone label says exogenous androgens shut down the body's own testosterone release and, at large doses, can suppress sperm production.3 The Alcohol and Drug Foundation says that when steroid use stops there is often a delay, sometimes lasting weeks or even months, before natural testosterone levels begin to recover.11 A review says most people recover hypothalamic-pituitary-gonadal function, but a subset have hypogonadism for months or even years.12 A 2021 systematic review by Vilar Neto and colleagues analysed 168 cases of hypogonadism linked to steroid abuse; of the 38 with fully known outcomes, it was completely reversible in 4.13 The two reviews describe different groups of people, so their recovery figures are not measuring the same thing.

Post-cycle therapy

The Alcohol and Drug Foundation says many turn to post-cycle therapy after a cycle, with other substances meant to support recovery.11 It lists tamoxifen, clomiphene, anastrozole and hCG as drugs commonly used.11 The Grant survey paper says post-cycle therapy to restore hormone function after stopping steroids is unproven, with no randomised controlled trials to support it.1 None of the labels, regulators or guidelines searched gives a regimen for stopping a non-medical cycle.

What people log for testosterone

Of people who logged testosterone, 17% logged under 100 mg a week, 21% 100 to 200 mg, 21% 200 to 300 mg, 22% 300 to 500 mg and 19% over 500 mg.14 Of people who logged testosterone enanthate, 14% logged a 250 mg dose and 9% a 150 mg dose.14

Frequently asked questions

What do labels say about use under 18?

The Depo-Testosterone label lists premature closure of the bony growth plates in adolescents among reported reactions.3

Is testosterone legal in the US and Australia?

The Depo-Testosterone label says the drug is a US Schedule III controlled substance.3 The Alcohol and Drug Foundation states that in Australia it is illegal to use, possess, manufacture, supply or import steroids without a valid prescription or medical licence.11

How the logged figures are counted

Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people.

References

  1. Substance Abuse Treatment, Prevention, and Policy, via Europe PMC. Grant 2023: use of post-cycle therapy and withdrawal symptoms from anabolic-androgenic steroid use, survey of 470 men (full text). 2023. ebi.ac.uk
  2. Hikma Pharmaceuticals, via DailyMed (US FDA label). Testosterone Enanthate Injection, USP, prescribing information (Hikma). 2025. dailymed.nlm.nih.gov
  3. Pfizer (Pharmacia & Upjohn), via DailyMed (US FDA label). Depo-Testosterone (testosterone cypionate) injection, prescribing information. 2025. dailymed.nlm.nih.gov
  4. Antares Pharma, via DailyMed (US FDA label). Xyosted (testosterone enanthate) injection, prescribing information. 2025. dailymed.nlm.nih.gov
  5. New England Journal of Medicine, via PubMed. Bhasin 1996, NEJM: effects of supraphysiologic doses of testosterone on muscle size and strength in normal men (randomised trial of 43 men). 1996. eutils.ncbi.nlm.nih.gov
  6. American Journal of Physiology Endocrinology and Metabolism, via PubMed. Bhasin 2001: testosterone dose-response relationships in healthy young men (randomised trial of 61 men). 2001. eutils.ncbi.nlm.nih.gov
  7. Archives of General Psychiatry, via PubMed. Pope 2000: effects of supraphysiologic doses of testosterone on mood and aggression in normal men (randomised crossover trial of 56 men). 2000. eutils.ncbi.nlm.nih.gov
  8. Endocrine Reviews, via PubMed. Pope 2014: adverse health consequences of performance-enhancing drugs, an Endocrine Society scientific statement. 2014. eutils.ncbi.nlm.nih.gov
  9. Becton Dickinson, via US FDA. 510(k) summary K212499, BD Insulin Syringe. 2021. accessdata.fda.gov
  10. Eli Lilly and Company, via DailyMed (US FDA label). Humulin R (insulin human) injection, prescribing information (U-100 vial). 2023. dailymed.nlm.nih.gov
  11. Alcohol and Drug Foundation (Australia). Anabolic steroids (drug facts). 2026. adf.org.au
  12. Frontiers in Endocrinology, via PubMed. van Os 2025: prolonged post-androgen abuse hypogonadism, potential mechanisms and a proposed standardized diagnosis. 2025. eutils.ncbi.nlm.nih.gov
  13. Andrologia, via PubMed. Vilar Neto 2021: anabolic androgenic steroid-induced hypogonadism, a reversible condition? A systematic review. 2021. eutils.ncbi.nlm.nih.gov
  14. Milligram app dose logs, aggregated and anonymous, the 90 days to 17 November 2026. Each figure is a share of people who set up or logged the item, and each share is of at least 50 people. How these figures are counted